60. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, et al. (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. FASEB J 20: 419–425. 61. Long-Smith CM, Sullivan AM, Nolan YM (2009) The influence of microglia on the pathogenesis of Parkinson’s disease. Prog Neurobiol 89: 277–287. 62. Reynolds AD, Stone DK, Mosley RL, Gendelman HE (2009) Nitrated a- synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol 182: 4137–4149. 63. Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL (2007) Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease. J Leukoc Biol 82: 1083–1094. 64. Austin SA, Floden AM, Murphy EJ, Combs CK (2006) Alpha-synuclein expression modulates microglial activation phenotype. J Neurosci 26: 10558–10563. 65. Barreiro O, Martin P, Gonzalez-Amaro R, Sanchez-Madrid F (2010) Molecular cues guiding inflammatory responses. Cardiovasc Res 86: 174–182. 66. Schwartz M (2010) ‘‘Tissue-repairing’’ blood-derived macrophages are essential for healing of the injured spinal cord: From skin-activated macrophages to infiltrating blood-derived cells? Brain Behav Immun 24: 1054–1057. 67. Rich RR, Fleisher TA, Shearer WT, Shroeder HW, Jr., Frew AJ, Weyand CM (2008) Clinical Immunology. Principles and Practice TA F, ed. Elsevier Inc. 68. Rentzos M, Nikolaou C, Andreadou E, Paraskevas GP, Rombos A, et al. (2007) Circulating interleukin-15 and RANTES chemokine in Parkinson’s disease. Acta Neurol Scand 116: 374–379. 69. Gangemi S, Basile G, Merendino RA, Epifanio A, Di Pasquale G, et al. (2003) Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson’s disease. Mediators Inflamm 12: 251–253. 70. Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, et al. (2009) Peripheral cytokines profile in Parkinson’s disease. Brain Behav Immun 23: 55–63. 71. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, et al. (2002) IFN- gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168: 3195–3204. 72. Stone DK, Reynolds AD, Mosley RL, Gendelman HE (2009) Innate and adaptive immunity for the pathobiology of Parkinson’s disease. Antioxid Redox Signal 11: 2151–2166. a-Syn and Innate Immunity 73. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 8: 382–397. 74. Colton CA, Wilcock DM (2010) Assessing Activation States in Microglia. CNS Neurol Disord Drug Targets 9: 174–191. 75. Bonifati V, Oostra BA, Heutink P (2004) Unraveling the pathogenesis of Parkinson’s disease: the contribution of monogenic forms. Cell Mol Life Sci 61: 1729–1750. 76. Spira PJ, Sharpe DM, Halliday G, Cavanagh J, Nicholson GA (2001) Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann Neurol 49: 313–319. 77. Golbe LI, Di Iorio G, Sanges G, Lazzarini AM, La Sala S, et al. (1996) Clinical genetic analysis of Parkinson’s disease in the Contursi kindred. Ann Neurol 40: 767–775. 78. Papapetropoulos S, Paschalis C, Athanassiadou A, Papadimitriou A, Ellul J, et al. (2001) Clinical phenotype in patients with alpha-synuclein Parkinson’s disease living in Greece in comparison with patients with sporadic Parkinson’s disease. J Neurol Neurosurg Psychiatry 70: 662–665. 79. Bostantjopoulou S, Katsarou Z, Papadimitriou A, Veletza V, Hatzigeorgiou G, et al. (2001) Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation. Mov Disord 16: 1007–1013. 80. Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172: 2731–2738. 81. Hoyer W, Antony T, Cherny D, Heim G, Jovin TM, et al. (2002) Dependence of alpha-synuclein aggregate morphology on solution conditions. J Mol Biol 322: 383–393. 82. Candiano G, Bruschi M, Musante L, Santucci L, Ghiggeri GM, et al. (2004) Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis 25: 1327–1333. 83. Wittig I, Braun HP, Schagger H (2006) Blue native PAGE. Nat Protoc 1: 418–428. 84. Saura J, Tusell JM, Serratosa J (2003) High-yield isolation of murine microglia by mild trypsinization. Glia 44: 183–189. PLoS ONE | www.plosone.org 13 October 2010 | Volume 5 | Issue 10 | e13481